RxDoctor Payments DataLook up a doctor →

Joseph Cinderella, MD

Interventional Cardiology · Salisbury, MDNPI 1407848609

Payments from drug & device makers

$71,556in general payments, 2019–2025

Across 474 payments — averaging $150.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$41K
  • Lilly USA, LLC$20K
  • Medtronic$2K
  • Abbott$901
  • Novartis$831
  • Boston Scientific$749
  • plus $5K from 32 others

What the payments were for

  • Consulting fees$450%
  • Speaking & faculty fees$58,56982%
  • Travel & lodging$1,5112%
  • Food & beverage$11,31716%
  • Education$1140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,556 in reported general payments places this provider in the 75th percentile of 71 interventional cardiology providers in Maryland.

See all interventional cardiology providers in Maryland

Medicare billing

Part B allowed, 2024
$677,093
Medicare patients
3,670
Services billed
15,932

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$94,429
JardianceEmpagliflozin81$85,279
EntrestoSacubitril/Valsartan54$71,236
XareltoRivaroxaban29$34,199
Repatha SureclickEvolocumab11$9,001
Metoprolol Succinate286$4,348
Nitroglycerin101$2,010
Amlodipine Besylate270$1,754
Warfarin Sodium104$1,324
Atorvastatin Calcium115$1,252
Losartan Potassium112$1,246
Valsartan31$1,206
Spironolactone129$963
Ezetimibe18$931
Diltiazem 24hr Er (Cd)Diltiazem Hcl17$573

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$375$94,42997 claims
Boehringer IngelheimJardiance$41,310$85,27981 claims
NovartisEntresto$831$71,23654 claims
Johnson & JohnsonXarelto$220$34,19929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 71 interventional cardiology providers in Maryland.

Other interventional cardiology in Salisbury

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →